Eli Lilly and Company (NYSE:LLY) Shares Purchased by Perkins Coie Trust Co

Perkins Coie Trust Co increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,571 shares of the company's stock after acquiring an additional 521 shares during the quarter. Eli Lilly and Company comprises 1.2% of Perkins Coie Trust Co's investment portfolio, making the stock its 23rd biggest position. Perkins Coie Trust Co's holdings in Eli Lilly and Company were worth $5,427,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the last quarter. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $8,407,908,000. Proficio Capital Partners LLC grew its holdings in shares of Eli Lilly and Company by 100,387.1% during the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after purchasing an additional 5,197,038 shares during the period. Wellington Management Group LLP increased its position in shares of Eli Lilly and Company by 19.0% during the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after purchasing an additional 2,012,129 shares during the last quarter. Finally, Capital International Investors raised its holdings in Eli Lilly and Company by 23.2% in the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after buying an additional 1,645,222 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LLY. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $0.78 during trading hours on Wednesday, hitting $807.97. The company had a trading volume of 2,606,766 shares, compared to its average volume of 3,652,784. The business has a 50 day moving average of $770.33 and a 200-day moving average of $800.86. The company has a market cap of $765.74 billion, a PE ratio of 69.00, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period last year, the company earned $2.58 earnings per share. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.